A weekly combination therapy of anti-PD1, TA99-Neo2/15 and DLnano-vaccines against Gp100, Tyrp1, and Trp2 significantly improved survival in a therapeutic murine B16F10 melanoma model, inducing complete response in a subset of mice. The gene discussed is TYRP1; the disease is melanoma.